JP6599447B2 - プラダー・ウィリー症候群を治療する方法 - Google Patents

プラダー・ウィリー症候群を治療する方法 Download PDF

Info

Publication number
JP6599447B2
JP6599447B2 JP2017515228A JP2017515228A JP6599447B2 JP 6599447 B2 JP6599447 B2 JP 6599447B2 JP 2017515228 A JP2017515228 A JP 2017515228A JP 2017515228 A JP2017515228 A JP 2017515228A JP 6599447 B2 JP6599447 B2 JP 6599447B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
carbetocin
composition according
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017515228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532316A (ja
JP2017532316A5 (enExample
Inventor
デングラス，パスカル
レイディ，マイケル
コーナー，ポール
アラガーサミィ，スダーコディ
Original Assignee
フェリング ベスローテン フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フェリング ベスローテン フェンノートシャップ filed Critical フェリング ベスローテン フェンノートシャップ
Publication of JP2017532316A publication Critical patent/JP2017532316A/ja
Publication of JP2017532316A5 publication Critical patent/JP2017532316A5/ja
Priority to JP2019181930A priority Critical patent/JP6921154B2/ja
Application granted granted Critical
Publication of JP6599447B2 publication Critical patent/JP6599447B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017515228A 2014-09-19 2015-09-14 プラダー・ウィリー症候群を治療する方法 Active JP6599447B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019181930A JP6921154B2 (ja) 2014-09-19 2019-10-02 プラダー・ウィリー症候群を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052957P 2014-09-19 2014-09-19
US62/052,957 2014-09-19
PCT/US2015/049911 WO2016044131A1 (en) 2014-09-19 2015-09-14 Method of treating prader-willi syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019181930A Division JP6921154B2 (ja) 2014-09-19 2019-10-02 プラダー・ウィリー症候群を治療する方法

Publications (3)

Publication Number Publication Date
JP2017532316A JP2017532316A (ja) 2017-11-02
JP2017532316A5 JP2017532316A5 (enExample) 2018-09-20
JP6599447B2 true JP6599447B2 (ja) 2019-10-30

Family

ID=54238564

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017515228A Active JP6599447B2 (ja) 2014-09-19 2015-09-14 プラダー・ウィリー症候群を治療する方法
JP2019181930A Active JP6921154B2 (ja) 2014-09-19 2019-10-02 プラダー・ウィリー症候群を治療する方法
JP2021041334A Pending JP2021098745A (ja) 2014-09-19 2021-03-15 プラダー・ウィリー症候群を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019181930A Active JP6921154B2 (ja) 2014-09-19 2019-10-02 プラダー・ウィリー症候群を治療する方法
JP2021041334A Pending JP2021098745A (ja) 2014-09-19 2021-03-15 プラダー・ウィリー症候群を治療する方法

Country Status (16)

Country Link
US (3) US10441627B2 (enExample)
EP (2) EP3193907B1 (enExample)
JP (3) JP6599447B2 (enExample)
CN (2) CN112773765A (enExample)
CA (1) CA2957224A1 (enExample)
DK (1) DK3666258T3 (enExample)
ES (2) ES2970059T3 (enExample)
FI (1) FI3666258T3 (enExample)
HR (1) HRP20240166T1 (enExample)
HU (1) HUE065829T2 (enExample)
LT (1) LT3666258T (enExample)
PL (1) PL3666258T3 (enExample)
PT (1) PT3666258T (enExample)
RS (1) RS65144B1 (enExample)
SI (1) SI3666258T1 (enExample)
WO (1) WO2016044131A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441627B2 (en) * 2014-09-19 2019-10-15 Ferring B.V. Method of treating prader-willi syndrome
US20190135859A1 (en) 2017-08-11 2019-05-09 Ferring B.V. Method of manufacturing a pharmaceutical composition
KR102704660B1 (ko) 2017-08-11 2024-09-06 훼링 비.브이. 약학적 조성물의 제조 방법
US10736894B2 (en) 2018-02-15 2020-08-11 Ovid Therapeutics Inc. Methods of treating developmental syndromes with PDE10A inhibitors
EP3852723B1 (en) * 2018-09-20 2025-11-05 ACADIA Pharmaceuticals Inc. Stable intranasal formulations of carbetocin
AU2019345313A1 (en) * 2018-09-20 2021-03-18 Levo Therapeutics, Inc. Carbetocin drug product and process for preparing same
WO2022133198A1 (en) * 2020-12-18 2022-06-23 The General Hospital Corporation Probiotics compositions and method of using the same to enhance growth and social function in children
WO2022200568A1 (en) 2021-03-26 2022-09-29 Ot4B Treatment of dysphagia

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544662B2 (en) 1993-06-17 2009-06-09 Carle Development Foundation Polypeptides useful for appetite suppression
US20070032410A1 (en) 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
US6894026B1 (en) 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US9023793B2 (en) 2006-09-29 2015-05-05 Retrophin, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
NZ581452A (en) 2007-06-07 2012-11-30 Kyalin Bioscience Inc Intranasal carbetocin formulations and methods for the treatment of autism
WO2009033770A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Calcitonin c-terminal flanking peptide for use as a therapeutic agent
KR20100057641A (ko) 2007-09-11 2010-05-31 몬도바이오테크 래보래토리즈 아게 인터메딘 ４７ 및 ５３ 펩티드의 치료적 용도
US20100204150A1 (en) 2007-09-11 2010-08-12 Dorian Bevec Use of a peptide as a therapeutic agent
WO2009033820A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
HRP20140716T1 (hr) * 2008-03-31 2014-08-29 Ferring B.V. Analozi oksitocina
NZ590732A (en) 2008-07-18 2012-09-28 Zafgen Inc Methods of treating an overweight or obese subject using fumagillin
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
ES2595251T3 (es) 2010-05-25 2016-12-28 Inserm - Institut National De La Santé Et De La Recherche Médicale Métodos y composición farmacéutica para el tratamiento de un trastorno alimentario con inicio temprano en un paciente
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
WO2012149472A2 (en) 2011-04-27 2012-11-01 Ignite Institute For Individualized Health Methods, compositions, and kits for treating and preventing neurological conditions
CN104870466B (zh) 2012-12-21 2018-05-18 霍夫曼-拉罗奇有限公司 作为催产素激动剂的肽
JP6263553B2 (ja) 2013-01-17 2018-01-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ疾患の処置のためのオキシトシン受容体アゴニスト
CA2949173A1 (en) 2014-06-03 2015-12-10 Caterina Bissantz Peptides as oxytocin agonists
CR20160562A (es) 2014-06-06 2017-01-06 Hoffmann La Roche Péptidos como agonistas de la oxitocina
CN106573958A (zh) 2014-08-07 2017-04-19 豪夫迈·罗氏有限公司 用于制备催产素类似物的方法
US10441627B2 (en) * 2014-09-19 2019-10-15 Ferring B.V. Method of treating prader-willi syndrome

Also Published As

Publication number Publication date
HUE065829T2 (hu) 2024-06-28
CN112773765A (zh) 2021-05-11
JP2017532316A (ja) 2017-11-02
EP3666258A1 (en) 2020-06-17
JP2021098745A (ja) 2021-07-01
SI3666258T1 (sl) 2024-04-30
EP3193907B1 (en) 2020-01-01
RS65144B1 (sr) 2024-02-29
WO2016044131A1 (en) 2016-03-24
ES2970059T3 (es) 2024-05-24
EP3666258B1 (en) 2023-11-15
HRP20240166T1 (hr) 2024-04-26
LT3666258T (lt) 2024-01-10
CN106714819A (zh) 2017-05-24
US10441627B2 (en) 2019-10-15
DK3666258T3 (da) 2024-02-05
US20240082344A1 (en) 2024-03-14
EP3193907A1 (en) 2017-07-26
JP2020019790A (ja) 2020-02-06
CA2957224A1 (en) 2016-03-24
PL3666258T3 (pl) 2024-04-08
JP6921154B2 (ja) 2021-08-18
PT3666258T (pt) 2024-02-01
ES2775425T3 (es) 2020-07-27
FI3666258T3 (fi) 2024-02-09
US20200129584A1 (en) 2020-04-30
US20170326200A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
JP6599447B2 (ja) プラダー・ウィリー症候群を治療する方法
US10092564B2 (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
Ward et al. Anesthetics and sedatives: toxic or protective for the developing brain?
WO2020176276A1 (en) A formulation for improving seizure control
BR112020005998A2 (pt) uso de formulação de fenfluramina na redução em número e em frequências de crises convulsivas em populações de pacientes
WO2019067413A1 (en) USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US20240024304A1 (en) Methods of managing conditioned fear with neurokinin receptor antagonists
AU2024204716A1 (en) Treatment of alopecia areata
KR20120050512A (ko) 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료
US20200121651A1 (en) Pramipexole for Use in the Treatment of Pain
AU2015363757B2 (en) Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
CN119384295A (zh) 以纹状体纹状小体的多巴胺d1信号为靶点的强迫性障碍的药物疗法
US8680145B1 (en) Compositions and methods for treatment of fear of medical procedures
Rondanelli et al. P1-346 No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease
Shua-Haim et al. P1-347 An investigation into the safety, tolerability, and efficacy of high dose rivastigmine treatment in Alzheimer's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190815

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191002

R150 Certificate of patent or registration of utility model

Ref document number: 6599447

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250